Pyxis Oncology (PYXS) FCF Margin (2024 - 2025)
Pyxis Oncology (PYXS) reported FCF Margin of 94.46% for Q4 2025, up 84.57% quarter-over-quarter from 612.16% in Q2 2025.
Pyxis Oncology (PYXS) FCF Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of FCF Margin data on file, last reported at 94.46% in Q4 2025.
- FCF Margin for Q4 2025 came in at 94.46%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 458.23% (down 9958.0% YoY), and the FY2025 annual result was 458.3%, down 9964.0% from the prior year.
- FCF Margin climbed to 94.46% in Q4 2025 per PYXS's latest filing, from 612.16% in the prior quarter.
- Over five years, FCF Margin peaked at 94.46% in Q4 2025 and troughed at 612.16% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -94.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -94.46% |
| Jun 30, 2025 | -612.16% |
| Mar 31, 2024 | -129.73% |